Do we need another selective estrogen receptor modulator for the adjuvant treatment of breast cancer?
作者信息
Shenkier T
出版信息
Curr Oncol. 2013 Aug;20(4):191-2. doi: 10.3747/co.20.1466.
Abstract
摘要
相似文献
1
Do we need another selective estrogen receptor modulator for the adjuvant treatment of breast cancer?我们是否需要另一种选择性雌激素受体调节剂用于乳腺癌的辅助治疗？
Curr Oncol. 2013 Aug;20(4):191-2. doi: 10.3747/co.20.1466.
2
Increased frequency of mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor.通过给予选择性雌激素受体调节剂后再给予芳香化酶抑制剂增加转移性乳腺癌的突变频率。
Oncol Lett. 2020 Aug;20(2):1231-1238. doi: 10.3892/ol.2020.11669. Epub 2020 May 22.
3
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.表皮生长因子受体（EGFR）和乳腺癌中扩增的雌激素受体调节剂（AIB1）用于预测乳腺癌辅助他莫昔芬治疗后的临床结局。
Breast Cancer Res Treat. 2008 May;109(2):255-62. doi: 10.1007/s10549-007-9645-1. Epub 2007 Jul 17.
4
A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials.选择性雌激素受体调节剂及国家外科辅助乳腺和肠道项目临床试验综述
Semin Oncol. 2003 Oct;30(5 Suppl 16):4-13. doi: 10.1053/j.seminoncol.2003.08.002.
5
Challenges in the endocrine management of breast cancer.乳腺癌内分泌治疗中的挑战。
Breast. 2003 Aug;12 Suppl 2:S2-19. doi: 10.1016/s0960-9776(03)80158-3.
6
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.选择性雌激素受体调节剂及结合雌激素/巴多昔芬联合疗法：对乳腺影响的综述
Post Reprod Health. 2015 Sep;21(3):112-21. doi: 10.1177/2053369115599090. Epub 2015 Aug 19.
7
Selecting adjuvant endocrine therapy for breast cancer.选择乳腺癌的辅助内分泌治疗。
Oncology (Williston Park). 2004 Dec;18(14):1733-44, discussion 1744-5, 1748, 1751-4.
8
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.选择性雌激素受体调节剂在乳腺癌和子宫内膜癌治疗中的综述。
Semin Oncol. 2002 Jun;29(3 Suppl 11):129-33. doi: 10.1053/sonc.2002.34065.
9
Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.他莫昔芬和其他抗雌激素药物的毒性和不良反应。
Pharmacol Ther. 2013 Sep;139(3):392-404. doi: 10.1016/j.pharmthera.2013.05.005. Epub 2013 May 24.
10
Raloxifene: a selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women.雷洛昔芬：一种用于降低绝经后女性浸润性乳腺癌风险的选择性雌激素受体调节剂。
Womens Health (Lond). 2007 Mar;3(2):139-53. doi: 10.2217/17455057.3.2.139.
本文引用的文献
1
Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: a retrospective analysis.托瑞米芬与他莫昔芬治疗可手术乳腺癌绝经前患者的疗效和耐受性：一项回顾性分析。
Curr Oncol. 2013 Aug;20(4):196-204. doi: 10.3747/co.20.1231.
2
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.雌激素受体阳性乳腺癌诊断后继续辅助他莫昔芬治疗 10 年与 5 年后停药的长期疗效：ATLAS，一项随机试验。
Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1.
3
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.他莫昔芬在绝经后乳腺癌中的应用：细胞色素P450 2D6起重要作用。
J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22.
4
Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.细胞色素 P-450 2D6 在托瑞米芬和他莫昔芬氧化代谢中的作用和药理意义。
Int J Cancer. 2013 Mar 15;132(6):1475-85. doi: 10.1002/ijc.27794. Epub 2012 Sep 14.
5
Toremifene versus tamoxifen for advanced breast cancer.托瑞米芬与他莫昔芬治疗晚期乳腺癌的比较。
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD008926. doi: 10.1002/14651858.CD008926.pub2.
6
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.细胞色素P450 2D6基因分型作为绝经后女性辅助性他莫昔芬获益的标志物：经验教训
J Natl Cancer Inst. 2012 Mar 21;104(6):427-8. doi: 10.1093/jnci/djs139. Epub 2012 Mar 6.
7
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.乳腺癌激素受体及其他因素与辅助他莫昔芬疗效的相关性：随机试验的患者水平荟萃分析。
Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.
8
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.美国临床肿瘤学会临床实践指南：激素受体阳性乳腺癌患者辅助内分泌治疗的更新。
J Clin Oncol. 2010 Aug 10;28(23):3784-96. doi: 10.1200/JCO.2009.26.3756. Epub 2010 Jul 12.
9
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.早期乳腺癌中辅助托瑞米芬或他莫昔芬的疗效极佳。
Cancer. 2010 May 15;116(10):2307-15. doi: 10.1002/cncr.24940.
10
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.托瑞米芬和他莫昔芬对早期乳腺癌疗效相同：国际乳腺癌研究组12 - 93和14 - 93试验的初步结果
Ann Oncol. 2004 Dec;15(12):1749-59. doi: 10.1093/annonc/mdh463.
Zotero 插件